{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-010300","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2022-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.143082+00:00","generated_at":"2026-06-27T13:18:06.383531+00:00","sec_items":["2.02"],"event_type":"litigation","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gilead settles Biktarvy patent litigation with ViiV for $1.25B upfront + 3% royalty through 2027","bullets":["One-time payment of $1.25B to ViiV in Q1 2022; pre-tax charge of $1.25B recorded in Q4 2021.","Ongoing 3% royalty on U.S. sales of Biktarvy and bictegravir products until October 5, 2027.","Settlement resolves all pending and potential claims across U.S. and international jurisdictions.","ViiV grants Gilead a broad worldwide license and covenant not to sue for bictegravir."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-010300","json":"https://secwatch.observer/filing/0001104659-22-010300.json","markdown":"https://secwatch.observer/filing/0001104659-22-010300.md","text":"https://secwatch.observer/filing/0001104659-22-010300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000110465922010300/0001104659-22-010300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000110465922010300/tm224824d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T13:18:06.383531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}